Authors
Loading...
Retrospective analysis shows comparable effectiveness in progression-free survival for NAB-paclitaxel versus gemcitabine in locoregionally advanced nasopharyngeal carcinoma.
You‐Ping Liu (2025) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: